Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.51 |
| ▸ | NQO2 | P16083 | 6/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805525 | 0.90 | MTNR1B (0.51) | MTNR1AHTR2AHTR2CHTR2BMTNR1B | |
| SCHEMBL1478135 | 0.90 | MTNR1B (0.51) | MTNR1AHTR2AHTR2CHTR2BMTNR1B | |
| SCHEMBL6797543 | 0.90 | MTNR1B (0.51) | MTNR1AHTR2AHTR2CHTR2BMTNR1B | |
| SCHEMBL15540347 | 0.86 | MTNR1A (0.43) | MTNR1ACYP19A1CYP11B1HTR2AHTR2C | |
| SCHEMBL607389 | 0.86 | CYP19A1 (0.52) | CYP19A1HTR2CDRD2DRD3 | |
| SCHEMBL22477091 | 0.81 | HTR2A (0.51) | MTNR1ACYP19A1CYP11B1HTR2AHTR2C | |
| SCHEMBL4132717 | 0.80 | MTNR1A (0.49) | MTNR1ACYP19A1CYP11B1HTR2AHTR2C | |
| SCHEMBL30715531 | 0.80 | MTNR1A (0.49) | MTNR1ACYP19A1CYP11B1HTR2AHTR2C | |
| SCHEMBL30715541 | 0.80 | MTNR1A (0.49) | MTNR1ACYP19A1CYP11B1HTR2AHTR2C | |
| SCHEMBL13363972 | 0.80 | DRD2 (0.53) | MTNR1ACYP19A1CYP11B1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636266-B2 | Indane-, indene-, azaindane-, and azaindene-amines as activators of serotonin receptors | Rivo Bio, Inc. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250228798-A1 | INDANE-, INDENE-, AZAINDANE-, AND AZAINDENE-AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS | Rivo Bio, Inc. | 2025-07-17 | — | — | US | disclosed |
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2021-05-06 | — | — | US | disclosed |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-10-20 | — | — | US | disclosed |
| US-20190218227-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-07-18 | — | — | US | disclosed |
| US-10179791-B2 | Spiro-cyclic amine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2019-01-15 | — | — | US | disclosed |
| US-9951084-B2 | Spiro-cyclic amine derivatives as S1P modulators | Abb Vie B.V. (NL) | 2018-04-24 | — | — | US | disclosed |
| EP-3144312-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | AbbVie B.V. (NL) | 2017-03-22 | — | — | EP | disclosed |
| EP-2590955-B9 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-02-22 | — | — | EP | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| WO-2002059081-A2 | UREA DERIVATIVES AS INHIBITORS OF CCR-3 RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-4963680-A | INTERMEDIATES FOR THERAPEUTIC DRUGS | SYNTHELABO (FR) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427598-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | MTNR1A 194/4885CYP19A1 2329/4885CYP11B1 504/4885 |
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | MTNR1A 6/4885CYP19A1 3511/4885CYP11B1 368/4885 |
| US-20190218227-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | MTNR1A 176/4885CYP19A1 2152/4885CYP11B1 448/4885 |
| US-10807991-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR1, S1PR3, S1PR2 | MTNR1A 194/4885CYP19A1 2329/4885CYP11B1 504/4885 |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | MTNR1A 189/4885CYP19A1 514/4885CYP11B1 145/4885 |
| US-20250228798-A1 | INDANE-, INDENE-, AZAINDANE-, AND AZAINDENE-AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS | HTR2A, HTR1A, HTR2C | MTNR1A 92/4885CYP19A1 585/4885CYP11B1 1761/4885 |
| US-12636266-B2 | Indane-, indene-, azaindane-, and azaindene-amines as activators of serotonin receptors | CNR1, HTR1A, HTR1B | MTNR1A 35/4885CYP19A1 675/4885CYP11B1 389/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | MTNR1A 12/4885CYP19A1 2761/4885CYP11B1 581/4885 |
| US-10179791-B2 | Spiro-cyclic amine derivatives as S1P modulators | S1PR3, S1PR1, S1PR2 | MTNR1A 958/4885CYP19A1 1552/4885CYP11B1 189/4885 |
| US-20210130364-A1 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | MTNR1A 194/4885CYP19A1 2329/4885CYP11B1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.